BHP Group Limited — Capital/Financing Update 2008

Jan 29, 2008

==> picture [155 x 59] intentionally omitted <==

ASX Announcement (283)

30 January 2008

Announcements Officer Company Announcements Office ASX Limited Exchange Centre Level 6, 20 Bridge Street SYDNEY NSW 2000

Chairman’s Letter describing Fund Raising and the Corporate Strategy

Please find attached a copy of the letter from the Virax Chairman, Michael Humphris, to be despatched today to shareholders describing the current Convertible Notes Issue and its importance to the future corporate strategy of the Company.

The above mentioned document will be made available on Virax’s website www.virax.com.au once released to the market.

Yours Sincerely,

==> picture [90 x 46] intentionally omitted <==

John Morrison Company Secretary

About Virax

Virax, based in Melbourne, Australia, is a biopharmaceutical company engaged in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. The Company’s lead product, VIR201, an HIV/AIDS immunotherapeutic (therapeutic vaccine), recently cleared by the U.S. FDA to begin Phase II trials, has completed two successful clinical trials in Australia with additional international studies planned. The Company has also submitted an application to the South African regulatory authority (MCC) to conduct a Phase I/IIa trial of VIR201. Funding for the African trial has been contributed by a consortium of global and South African resource companies led by BHP Billiton.

In March 2007 Transgene (Eurolist Paris: FR0005175080) executed a Licence Agreement with the Company for access to Co-X-Gene™ technology for use in two of Transgene’s immunotherapeutic products. These are TG4001 – a treatment for pathologies relating to human papilloma virus (HPV) infection that can lead to cervical cancer - and TG4010 – a treatment for non-small cell lung cancer. This was reported to the ASX in the Company’s announcement of 13 March 2007 and is referred to as the “Transgene Sub-licence”. Both TG4001 and TG4010 are in advanced development with Phase III trials of TG4001 planned for 2008 and Phase IIb studies of TG4010 currently underway. Transgene has licensed TG4001 to the pharmaceutical company Roche for treatment of HPV related pathologies.

Additional information about Virax is available at www.virax.com.au

For further information contact:

Dr Larry Ward	John Morrison
CEO, Virax Holdings Limited	Company Secretary & CFO, Virax Holdings Limited
Melbourne, Australia	Melbourne, Australia
(03) 9854 6230	(03) 9854 6230

Virax Holdings Limited ABN 56 006 569 106 Suite 220 89 High Street Kew Victoria Australia 3101 Telephone +61 (0) 3 9854 6230 Facsimile+61 (0) 3 9853 5134 www.virax.com.au email: virax@virax.com.au

==> picture [132 x 72] intentionally omitted <==

000001 000 1301011221012102012221332120133322113 VHL MR JOHN SMITH 2 FLAT 123 123 SAMPLE STREET THE SAMPLE HILL SAMPLE ESTATE SAMPLEVILLE VIC 3030

==> picture [483 x 507] intentionally omitted <==

VHL_WIP_102533/000001/000001/i

==> picture [483 x 233] intentionally omitted <==